As Germany readies for adult-use, Curaleaf of Wakefield, MA — a leading U.S. provider of consumer products in cannabis — today announced an agreement to acquire a 55 percent stake in Four 20 Pharma, among the largest cannabis operators in Germany.
Focused on bringing top quality flower to market, Four 20 Pharma is a fully EU-GMP & GDP licensed German producer and distributor of medical cannabis. Launching its own product line, “420Natural” in 2020, the company based in Paderborn, Germany owns a greater than 10% market share and has established distribution nationally.
Boris Jordan, Curaleaf executive chairman, stated, “This strategic transaction further underscores our aspiration to be the major player in the European market and the leading global cannabis company.”
Germany currently represents the largest medical cannabis market in Europe. Currently valued $205 million, it is expected to grow to nearly $1 billion by the end of 2024 as adult-use legalization begins in late 2023 or early 2024.
Curleaf’s European holding company, signed the $20 million deal through which Curaleaf will acquire complete control of Four 20 Pharma within two years of the commencement of adult use in Germany.
Thomas Schatton, Managing Partner of Four 20 Pharma, added, “The team at Four 20 are thrilled to be able to leverage Curaleaf’s proven R&D expertise to help us continue delivering the best quality products to our medical patients and the promising future adult use market.”
For more information, please visit here.